

## PE Anti-Human CD11c Monoclonal Antibody



天津三箭生物技术股份有限公司  
Tianjin Sungene Biotech Co., Ltd.  
精准 高效 稳定 Precision Efficient Stable

Catalog Number	Vial Size
H30111-09G	25 tests
H30111-09H	100 tests

**Market** | 400-621-0003  
marketing@sungenebiotech.com

**Support** | 022-66211636-8024  
techsupport@sungenebiotech.com

**Web** | www.sungenebiotech.com

**Important Note:** Centrifuge before opening to ensure complete recovery of vial contents.  
This product is guaranteed up to one year from purchase.

### Purified Antibody Characterization


Clone	Isotype	Reactivity
3.9	Mouse IgG1	Human*

\*Cross-Reactivity: Chimpanzee, Baboon, African Green, Cynomolgus, Rhesus, Squirrel Monkey

### Description

Clone 3.9 preferentially binds the activated form of CD11c, is specific for I domain of CD11c, and is able to partially block the binding of CD11c and ICAM-4. 3.9 binding is divalent cation dependent. While analyzing blood, it is best to use heparin as the anti-coagulant and not EDTA. Since the ability of clone 3.9 to bind to its target is divalent cation dependent, the usage of EDTA as an anti-coagulant may be detrimental to staining due to its chelating properties.

### Illustration of Immunofluorescent Staining



Human peripheral blood granulocytes stained  
with PE anti-human CD11c

### Product Information

**Conjugation:** PE

**Formulation:** Aqueous buffer, 0.09% NaN<sub>3</sub>, may contain carrier protein/stabilize.

**Storage:** Keep as concentrated solution. Store at 4°C and protected from prolonged exposure to light. **Do not freeze.**

**Application:** Recommended Application: FC

**Usage:** Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis (The amount of the reagent is suggested to be used 20 µL to 5 µL /10<sup>6</sup> cells or 100 µL of whole blood. Please check your vial). Since applications vary, the appropriate dilutions must be determined for individual use.

### References

- [1] Schlossman S, et al.
- [2] Knapp W, et al.
- [3] McMichael A, et al. Eds.
- [4] Vainer B, et al. 2000.
- [5] Ottonello L, et al.
- [6] Asai A, et al. 2009.

**For Research Use Only.**